Illumina is off to a racing start in 2016, and the pace isn't showing any signs of slowing. The company is snatching up Conexio Genomics to get its hands on Conexio's transplant genotyping products, a couple of weeks after it unveiled its liquid biopsy spinoff and expanded genomics offerings.
Toshiba appears on track to earn more than $3 billion from the sale of its medical device unit to help it recover from an accounting scandal, as the list of companies bidding on Toshiba Medical Systems grows, just prior to the Friday deadline.
Struggling drugmaker MannKind is looking for a way out of its perilous financial situation, according to Reuters, scouting for a buyer in the wake of ex-partner Sanofi's decision to abandon the company and its inhaled insulin.
After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.
U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling.
XenoPort, a month removed from deep job cuts, is looking to sell itself, according to Reuters, reaching out to potential acquirers after a string of R&D; disappointments.
Acquisitive CRO BioClinica bought a firm that specializes in handling the financial side of clinical trials, picking up technology that automates how sponsors and contractors pay for studies.
Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale.
Acorda Therapeutics has swooped in to buy Finland's Biotie for $363 million in cash, snagging a Phase III Parkinson's drug that is being lined up to follow its leading experimental drugs into the neurology market.
HeartWare's acquisition of Israeli cardiac implant maker Valtech Cardio is now in even greater jeopardy. Reuters reports that a second group of activist investors, led by former J.P. Morgan CFO Doug Braunstein, purchased a 5% stake in the struggling company in hopes of blocking the transaction.